Know Cancer

or
forgot password

Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma


Phase 2
18 Years
N/A
Not Enrolling
Both
Skin Cancer, Melanoma, Metastatic Melanoma

Thank you

Trial Information

Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma


Background:

- Tumor Infiltrating Lymphocytes (TIL) can mediate the regression of bulky metastatic
melanoma when administered to the autologous patient along with high-dose aldesleukin
(IL-2) following a non-myeloablative lymphodepleting chemotherapy preparative regimen.

- Although this adoptive cell therapy (ACT) has been shown capable of mediating objective
clinical responses in patients with metastatic melanoma, including patients who have
previously been treated with aldesleukin or chemotherapy, the treatment is only
available in the Surgery Branch, National Cancer Institute (NCI) and in just one or two
other institutions in the United States.

- Despite our reports of the objective regressions in patients receiving adoptive cell
therapy (ACT), doubts have been raised concerning the possible influence of patient
selection bias that may have accounted for the increase in survival using ACT compared
to historical controls.

- ACT is a cumbersome and labor intensive procedure which has discouraged many from
applying it. We have recently developed simplifications in the technique for generating
TIL that are also capable of mediating objective responses.

- To evaluate the efficacy of ACT we are now proposing a prospective randomized trial to
compare this form of therapy with standard available treatment for patients with
metastatic melanoma.

Objectives:

- To determine, in a prospective randomized trial, the response rate and progression free
survival of patients with metastatic melanoma receiving either ACT or standard
high-dose aldesleukin treatment.

- Survival rate will be evaluated as a secondary endpoint.

- To determine the toxicity of these two treatment regimens.

Eligibility:

Patients who are 18 years of age or older must have:

- Evaluable metastatic melanoma;

- No prior treatment with high-dose aldesleukin (greater than or equal to 600,000 IU IL-2
q8h or the equivalent)

- No contraindications to high-dose aldesleukin administration;

- No concurrent major medical illnesses or any form of immunodeficiency;

- Lesions of at least 2cm in diameter that can be surgically removed with minimal
morbidity.

Design:

- Prior to amendment D, patients with metastatic melanoma lesions that can be resected
with minimal morbidity will be prospectively randomized to receive either ACT using
CD8+ young TIL (arm 2) and aldesleukin (arm 1) following a non-myeloablative
chemotherapy preparative regimen, or will receive standard high-dose aldesleukin
therapy.

- With the approval of amendment D, arm 1 and 2 will be closed, and two new arms will be
opened. Patients with metastatic melanoma lesions that can be resected with minimal
morbidity will be prospectively randomized to receive either ACT using young TIL (arm
4) and aldesleukin (arm 3) following a non-myeloablative chemotherapy preparative
regimen, or will receive standard high-dose aldesleukin therapy.

- Response rate and time to progression will be evaluated for all patients on an
intent-to-treat basis.

- Patients may crossover to the other treatment arm after progressive disease is
documented by Response Evaluation Criteria in Solid Tumors (RECIST) criteria, if still
eligible.

Inclusion Criteria


- INCLUSION CRITERIA:

1. Measurable metastatic melanoma with at least one lesion that is resectable for
tumor infiltrating lymphocytes (TIL) generation. The lesion must be of at least
2cm in diameter that can be surgically removed with minimal morbidity (defined
as any operation for which expected hospitalization is less than or equal to 7
days).

2. Patients with 3 or less brain metastases are eligible. Note: If lesions are
symptomatic or greater than or equal to 1 cm each, these lesions must have been
treated and stable for 3 months for the patient to be eligible.

3. No prior high-dose aldesleukin therapy at a dose of greater than or equal to
600,000 IU/kg.

4. Greater than or equal to 18 years of age.

5. Willing to practice birth control during treatment and for four months after
receiving all protocol related therapy.

6. Life expectancy of greater than three months.

7. Willing to sign a durable power of attorney.

8. Able to understand and sign the Informed Consent Document.

9. Clinical performance status of Eastern Cooperative Oncology Group (ECOG) 0 or 1.

10. Hematology:

- Absolute neutrophil count greater than 1000/mm^3 without support of filgrastim

- Normal White blood cell (WBC) (> 3000/mm^3).

- Hemoglobin greater than 8.0 g/dl

- Platelet count greater than 100,000/mm^3

k. Serology:

- Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental
treatment being evaluated in this protocol depends on an intact immune system.
Patients who are HIV seropositive can have decreased immune competence and thus be
less responsive to the experimental treatment and more susceptible to its
toxicities.)

- Seronegative for hepatitis B antigen, or hepatitis C antibody or antigen.

l. Chemistry:

- Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) less than three
times the upper limit of normal.

- Calculated creatinine clearance estimated glomerular filtration rate(eGFR) > 50
ml/min.

- Total bilirubin less than or equal to 2 mg/dl, except in patients with Gilbert's
Syndrome who must have a total bilirubin less than 3 mg/dl.

m. More than four weeks must have elapsed since any prior systemic therapy at the
time the time of randomization, and patients' toxicities must have recovered to a
grade 1 or less (except for alopecia or vitiligo). Patients must have stable or
progressing disease after prior treatment. Patients may have undergone minor surgical
procedures within the past 3 weeks, as long as all toxicities have recovered to grade
1 or less or as specified in the eligibility criteria.

n. Six weeks must have elapsed since any prior anti-CTLA4 antibody therapy to allow
antibody levels to decline.

o. Patients who have previously received any cytotoxic T-lymphocyte antigen 4
(anti-CTLA4) antibody and have documented gastrointestinal (GI) toxicity must have a
normal colonoscopy with normal colonic biopsies.

EXCLUSION CRITERIA:

1. Prior cell transfer therapy which included a non-myeloablative or myeloablative
chemotherapy regimen.

2. Women of child-bearing potential who are pregnant or breastfeeding because of the
potentially dangerous effects of the preparative chemotherapy on the fetus or infant.

3. Systemic steroid therapy requirement.

4. Active systemic infections, coagulation disorders or other active major medical
illnesses of the cardiovascular, respiratory or immune system, as evidenced by a
positive stress thallium or comparable test, myocardial infarction, cardiac
arrhythmias, obstructive or restrictive pulmonary disease.

5. Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
Disease and Acquired Immunodeficiency Syndrome (AIDS)).

6. Opportunistic infections (The experimental treatment being evaluated in this protocol
depends on an intact immune system. Patients who have decreased immune competence may
be less responsive to the experimental treatment and more susceptible to its
toxicities.)

7. History of severe immediate hypersensitivity reaction to any of the agents used in
this study.

8. History of coronary revascularization or ischemic symptoms.

9. Any patient known to have an left ventricular ejection fraction (LVEF) less than or
equal to 45%.

10. In patients > 60 years old, documented LVEF of less than or equal to 45%.

11. Documented forced expiratory volume 1 (FEV1) less than or equal to 60% predicted
tested in patients with:

- A prolonged history of cigarette smoking

- Symptoms of respiratory dysfunction

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response Rate

Outcome Description:

Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD. Progressive disease (PD) is at least a 20% increase in the sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD.

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

Ramaprasad Srinivasan, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

National Cancer Institute (NCI)

Authority:

United States: Federal Government

Study ID:

100117

NCT ID:

NCT01118091

Start Date:

April 2010

Completion Date:

April 2012

Related Keywords:

  • Skin Cancer
  • Melanoma
  • Metastatic Melanoma
  • Immunotherapy
  • Metastatic Melanoma
  • Randomized
  • Cell Therapy
  • Skin Cancer
  • Melanoma
  • Skin Neoplasms
  • Melanoma

Name

Location

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland  20892